Spinal Cord Stimulation (SCS) External Pulse Generator (EPG)
ABBOTT MEDICAL · Decision date Oct 28, 2026
What did the FDA decide?
The FDA record for P010032/S262, dated 2026-10-28, is a 30-Day Notice supplement to Abbott Medical's spinal cord stimulation premarket approval. The recorded statement covers qualification of an alternate antenna component used in Abbott's Spinal Cord Stimulators, Deep Brain Stimulators, and Dorsal Root Ganglion External Pulse Generators. The listed supplement reason is a process change involving manufacturer, sterilizer, packager or supplier.
The decision code is OK30, and the device category is a totally implanted spinal-cord stimulator for pain relief, under product code LGW in Neurology. This entry documents a component and supplier-related change within the existing approval rather than a new approval of the whole system. The record does not include the supporting documents, the antenna specifications, or any conditions attached to the decision, so those details remain unknown from this source.
FDA approval order statement
qualification of an alternate antenna component utilized in Abbott's Spinal Cord Stimulators (SCS), Deep Brain Stimulators (DBS), and Dorsal Root Ganglion (DRG) External Pulse Generators (EPG)
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Oct 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010032/S262
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LGW
- Decision code
- OK30
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Abbott Medical
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010032 · Original PMA
GENESIS AND EON FAMILY NEUROSTIMULATION (IPG) SYSTEMS
P010032/S261 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S251 · Related supplement
Quattrode; Octrode; Penta; Lamitrode; Tripole; TriCentrus Lead Extensions
P010032/S260 · Related supplement
Proclaim family of SCS IPG
P010032/S262 received
Application receipt date recorded by FDA.
P010032/S265 · Related supplement
Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generator
P010032/S262 · FDA decision
30-Day Notice
P010032/S264 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger
P010032/S266 · Related supplement
Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG)
Timeline entries are records held by MedtechLedger for P010032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Nov 21, 2001 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 11, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Sep 18, 2026 | FDA | |
Proclaim family of SCS IPGP010032/S260 | ABBOTT MEDICAL | PMA supplement | Sep 23, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Oct 27, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 6901 Preston Rd., Plano, TX, 75024
Sources and methodology
- Original FDA record: P010032/S262
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






